What is the study about?
This study looks at the safety and effectiveness of the anti-depressant escitalopram in treating agitation in people with Alzheimer’s disease. Participants and their caregiver(s) will receive psychosocial counselling to address agitation in Alzheimer’s disease. Participants who do not show a response will be given, at random, either escitalopram or placebo.
Eligibility- Who can participate?
- Have a diagnosis of Alzheimer’s dementia
- Have symptoms of frequent agitation and aggression
- Have a caregiver who spends at least several hours per week with the participant, supervises their care, is willing to accompany the participant to study visits, and is willing to participate in the study
- Be available for 6 months’ follow-up
6 in-person visits (2-3 hours each) every 3 weeks and 7 telephone contacts over 6 months. Each visit will involve assessments of mood and cognition, questionnaires, blood work and heart monitoring (ECG), and psychosocial counselling.
TDRA study investigators
CAMH: Drs. Tarek Rajji, Sanjeev Kumar and Bruce Pollock
Sunnybrook: Drs. Krista Lanctôt and Nathan Herrmann
Centre for Addiction and Mental Health (CAMH)
Address: 1001 Queen St W, Toronto, ON M6J 1H4Sunnybrook Health Sciences Centre